COVID-19 News: New COVID-19 Vaccine Efficacy, MIS-C, and More

COVID-19 multisystem inflammatory syndrome observed in adults

A 60-year-old Canadian man was diagnosed with multisystem inflammatory syndrome (MIS-C), a rare side effect of COVID-19 in children. The study, published in the Canadian Medical Association Journal, suggests that age should not limit MIS-C as a possible diagnosis. His symptoms were persistent shortness of breath, high fever, swelling, and severe fatigue. Subsequent tests showed increased swelling of the heart and lungs.

2 studies suggest that post-COVID syndrome therapy in children is difficult to treat

Two real-world studies looking at the use of intravenous immunoglobulin (IVIG) therapy plus glucocorticoids to treat post-COIVD-19 MIS-C in children were inconclusive. One found a lower risk of new or persistent cardiovascular problems, while the other had no effect. An accompanying editorial suggested that while they had conflicting conclusions, they were referring to very different populations and using data from two different periods of the pandemic. Inadequacies may also have occurred in the statistical modeling methods used.

Moderna increases overall production

While the COVID-19 pandemic was the worst in over 100 years, the crisis has produced the best in the life sciences as companies around the world continue to respond to the call. Modern, is the second company to have its COVID-19 vaccine approved by the FDA Add two new production lines in the converted former Polaroid factory to increase the total production capacity by 50%. With the expansion of the 350,000 square foot site, there is a persistent rental flood for the area. Moderna originally employed 150 people in 2018 and has created more than 650 new jobs at its Norwood, Massachusetts site.

Using the anti-parasitic drug ivermectin for COVID-19

Use of the anti-parasitic drug ivermectin could reduce deaths related to COVID-19, data from a Peer-reviewed study shows. The Study, published last week by doing American Journal of Therapeutics, analyzed data from multiple clinical trials evaluating ivermectin as a potential treatment for COVID-19. Ivermectin, approved by the U.S. Food and Drug Administration (FDA) for the treatment of intestinal strongyloidiasis and onchocerciasis, two conditions caused by parasitic worms, has anti-inflammatory properties.

COVID-19 and ongoing neurological effects

The COVID-19 pandemic may be easing, but for patients, the aftereffects can linger for months. Researchers at the virtual 7th congress of the European Academy of Neurology (EAN) consistently report significant, persistent cognitive and behavioral problems in several studies. The problem of neurological sequelae is often underrated, and may increase patient exposure to COVID-19, according to neurologists R. Garcia Santos, MD, and M. Rodriguez Rodriguez, MD, of Mexico City.

Instructions for long COVID

Long COVID, or long distance syndrome, is a puzzling series of persistent symptoms and complications following COVID-19 infection. Last week the U.S. Centers for Disease Control and Prevention (CDC) new instructions issued for long COVID, loosely defined as illness at least four weeks after an acute infection. The guide notes that general practitioners can typically handle conditions post-COVID, but objective laboratory or imaging results “should not be used as the sole measure or assessment of a patient’s wellbeing; The absence of laboratory or visual abnormalities does not invalidate the existence, severity, or significance of a patient’s symptoms or conditions. “

Oral rheumatoid arthritis according to Pfizer

Treatment with Pfizers The oral drug Xeljanz (tofacitinib) for rheumatoid arthritis has been linked to a reduction in deaths or respiratory failure in hospitalized patients with COVID-19-related pneumonia Results from studying in Brazil. Results from the placebo-controlled STOP-COVID study, released by doing New England Journal of Medicine, suggest that the oral Janus kinase (JAK) inhibitor tofacitinib could be a potential contender in the race for the benefits of COVID-19 in previously approved therapies. The therapy is currently approved for rheumatoid arthritis, but not for COVID-19 or COVID-19-related pneumonia.

CureVac’s COVID-19 vaccine is only 47% effective

CureVacs COVID-19 vaccine candidate CVnCoV has shown According to an interim analysis of the international phase IIb / III study HERALD, only 47% effective against COVID-19 disease of any severity. The new findings are likely to thwart the company’s plans to soon deliver millions of urgently needed vaccine doses to the European Union. After the news of the results, CureVac’s US-traded shares fell 50.6% to $ 46.81 in after-hours trading. In the German trade, too, the company’s shares plummeted by more than 52%. as reported by Bloomberg, which reportedly wiped out a market value of nearly $ 9.6 billion.

COVID-19 origin

While the science has not changed regarding the novel coronavirus responsible for COVID-19, some virologists and officials have call for further investigation into the origins of the virus, particularly regarding a China-based laboratory leak theory endorsed by former President Donald Trump. Last month did a group of 18 scientists published an open letter in science Ask leaders of global health organizations to further investigate the origin of SARS-CoV-2. The scientists asked to investigate theories about the virus’s natural occurrence, as well as laboratory spillovers.

Regeneron’s COVID-19 antibody cocktail

Regenerons COVID-19 antibody cocktail REGEN-COV continues Demonstrate effectiveness against the coronavirus. Data from a new UK study show REGEN-COV rdecreased the risk of death in hospitalized patients unable to build their own immune response by 20%.

Intranasal therapy for COVID-19

Another company developing intranasal therapy for COVID-19 has risen above from below below how ENA respiratory system announced A $ 32 million funding and appointment of COPD Foundation President and Scientific Director Dr. Ruth Tal-Singer, Ph.D. to bring the nasal spray to market.

Recycled drug for COVID-19

Reused drugs became the first line of defense against COVID-19 within months of the pandemic outbreak. Now, bucillamine, which is currently in Phase III trials in the US, could be close to joining them. Used to treat arthritis in Japan and South Korea for 30 years, Canadian company Revive Therapeutics puts it through its paces as a possible oral home therapy for mild to moderate COVID-19.

COVID-19 vaccines and the Delta variant

New data shows COVID-19 vaccines are effective against the Delta variant, a strain of concern that is fueling infections in India, England, Scotland and other countries around the world and causing governments to suspend reopening plans. One recently study carried out by Public Health England found that the vaccines available were “highly effective” at preventing hospitalization. The government report found that the mRNA vaccine developed by Pfizer and BioNTech is 96% effective against hospitalization after two doses and the AstraZeneca The vaccine is 92% effective against hospitalization after two doses.

Pfizers preparing for the next pandemic

A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTechmRNA vaccine during the height of the COVID-19 pandemic. As the crisis seems to be easing, Pfizer is Prepare for the next pandemic. “The scenario that a variant of the virus will one day bypass the vaccine is real,” said Albert Bourla, CEO and Chairman of Pfizer, DVM, Ph.D BIO-Digital 2021. “We have tested our vaccine against almost all SARS-CoV-2 variants, including the latest (from India and called Delta), and no variant escapes our vaccine.”

AstraZeneca’s antibody did not meet the primary endpoint

Shares in AstraZeneca broke into pre-trading hours after the company announced that its COVID-19 antibody therapeutics are not providing high levels of protection for those who have had contact with a symptomatic COVID-19 patient. AstraZeneca said that Phase III study STORM CHASER Assessment of AZD7442, a combination of long-acting antibodies (LAAB), failed to meet the primary endpoint the post-exposure prevention of symptomatic COVID-19 versus placebo. The failure is a setback in the search for means other than vaccines to protect against the novel coronavirus and its variants.

About Ellen Lewandowski

Check Also

Are you struggling to demonstrate your value as a board member? Developing… – Women of Influence

By Kristi Honey On May 21, 2022, a devastating tornado made landfall in the Ontario …

Leave a Reply

Your email address will not be published.